As Q1'26 earnings roll in, corporate reports are outperforming consensus in a way not often seen in recent years. According to the data cited by the models, 84% of companies that have reported so far have beaten earnings-per-share estimates, and 81% have posted revenue figures above forecasts. Those surprises have helped push major market benchmarks to their strongest monthly performance since the pandemic.
Against that backdrop, subscribers to an AI-powered equity-selection service, available for under $9 per month, received early recommendations that have already generated notable gains. One particularly strong recommendation was a North Carolina-based provider of advanced analytics, technology solutions, and contract research services to the life sciences and healthcare industries. That company rallied by 11.82% in April alone following a positive earnings release.
Other recent model-identified stocks also recorded meaningful monthly advances. Among the May selections, several names have already climbed by more than 5% in the month:
- Republic Airways Holdings Inc (NASDAQ: RJET): +9.25% in May alone
- NGL Energy Partners LP (NYSE: NGL): +8.46% in May alone
- Teradata Corp (NYSE: TDC): +7.58% in May alone
- Alexandria Real Estate Equities Inc (NYSE: ARE): +5.82% in May alone
- Applied Materials Inc (NASDAQ: AMAT): +5.59% in May alone
The same AI-driven selection process also flagged a number of names that produced very large rallies in April. Several companies advanced by more than 40% during that month, including:
- Centene (NYSE: CNC): +58.11% in April alone
- Molina Healthcare (NYSE: MOH): +43.17% in April alone
- Texas Instruments (NASDAQ: TXN): +43.16% in April alone
- Qualcomm (NASDAQ: QCOM): +41.06% in April alone
IQVIA: a concentrated, multi-strategy signal
For the May selection set, the models singled out IQVIA Holdings (IQV) across three different strategies, making it the highest-conviction pick for the month. Following an earnings report that beat expectations, the stock jumped roughly 9.6% on the day, bringing its total gain to approximately 11.82% over a short period.
The quarterly numbers cited for IQVIA were narrowly above consensus: EPS of $2.90 versus an expected $2.82, and revenue of $4.15 billion versus an expected $4.10 billion. Those results are the type of outcome that can trigger a decisive post-report move when investors re-evaluate prior discounts.
The AI models identified several factors that, when combined, formed a high-conviction opportunity prior to the rally. The framework highlighted three themes:
- Unwarranted selloff - The stock had declined nearly 30% year-to-date amid market concerns about AI disruption in healthcare. The models noted that multiple analysts, including Barclays and TD Cowen, judged those disruption fears to be overstated and had upgraded the name.
- Valuation dislocation - At roughly $157 per share, the models observed the stock was trading about 47% below a consensus analyst fair value near $232, creating what the system classified as a deeply discounted growth opportunity.
- Improving fundamentals and AI adoption - The business showed momentum after a strong Q4 2025, when revenue reached $4.4 billion, up more than 10% year-over-year. Management issued bullish guidance for 2026, projecting up to $17.4 billion in revenue and EPS in the $12.55 to $12.85 range. Separately, the newly launched IQVIA.ai platform, powered by NVIDIA technology, was already integrated into the workflows of 19 of the top 20 pharmaceutical firms, suggesting the firm views AI as an accelerator rather than a threat.
Because IQVIA appeared across multiple strategies simultaneously, the service interprets that concurrence as an unusually strong alignment across distinct quantitative signals - including valuation, momentum, earnings quality, analyst revisions, and growth prospects. For subscribers, seeing the same stock flagged by independent model constructions can increase conviction ahead of broader market recognition.
Other model successes and positioning ahead of earnings
The patterns the service identified for IQVIA are not isolated. The models also highlighted other names that have paid off for early followers. Examples cited include:
- Kyndryl (KD) - Investors who acted when the company appeared on the March list are reported to be up about 19.22%.
- Applied Materials (AMAT) - Early purchasers identified by the model in April saw gains of about 16.12%.
- Teradata (TDC) - Those who positioned on the May update saw gains of about 7.58%.
Because earnings season moves quickly, the service emphasizes the value of being positioned ahead of results. A new roster of AI-picked stocks for May is now live, and several of the selections highlighted - including providers such as Autodesk (ADSK) and Maximus - have not yet reported, which the model suggests could create additional opportunities for investors who enter prior to their respective reports.
Subscribers to the ProPicks offering receive not only the list of selections but also the detailed rationale driving each inclusion and removal across the strategies, allowing users to review the specific data signals that prompted each decision.
How the AI selection engine operates
The AI system described evaluates thousands of global equities at the start of each month. It combines historical performance data, valuation indicators, and forward-looking growth metrics, processing more than 15 years of financial information across over 150 quantitative models. The engine then identifies up to 20 high-conviction stocks per strategy based on medium-term upside potential.
Each strategy undergoes monthly rebalancing: fresh opportunities are added, strong performers are retained, and names that no longer meet the selection criteria are removed. To measure performance consistently, the strategies use equal weighting across their selected stocks, though individual investors are free to adjust allocations to their preference. The stated objective of the framework is to systematically reallocate capital toward the most compelling opportunities as market conditions evolve.
Subscription pricing referenced in the underlying material was accurate at the time of publication and may vary by region as offers are tested.